Deltex Medical Group PLC Directorate Change (8920O)
07 October 2019 - 5:00PM
UK Regulatory
TIDMDEMG
RNS Number : 8920O
Deltex Medical Group PLC
07 October 2019
7(th) October 2019
Deltex Medical Group plc
("Deltex" or the "Company" or the "Group")
Directorate change
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring, announces that Jonathan Shaw has
resigned as Finance Director and as a Director of the Company with
effect from 4(th) October 2019. Under the terms of his contract Mr
Shaw's employment with the Group will end on or before 4(th) April
2020.
The Group has started a process to appoint a new Finance
Director and has engaged the services of David Moorhouse, a former
Finance Director of the Group, to oversee the financial function in
the interim whilst a suitable new candidate is found for the
permanent Finance Director role. Mr Moorhouse will also become
Group Company Secretary.
Mr Shaw has been with Deltex since 2015 and during that time has
participated in implementing the substantial changes that have
brought the Group to its current position. With the Group now in a
stable position Mr Shaw feels that it is an appropriate time for
him to pursue his career in a new assignment.
Andy Mears, CEO of Deltex, said:
"Jonathan Shaw has helped me successfully implement the Group's
new strategy by working with me to create a stable financial
platform from which we can move forward. I would like to thank him
for his contribution to Deltex and wish him every good fortune in
his future career."
Nigel Keen, Chairman of Deltex, said:
"On behalf of the Board, I want to thank Jonathan Shaw for his
work and dedication to Deltex over the last four years. During this
time the Group has stabilised and now has a strong business and
financial base from which it can move forward."
Deltex Medical Group plc 01243 774 837
investorinfo@Deltexmedical.com
Nigel Keen, Chairman
Andy Mears, Chief Executive
Nominated Adviser & Joint Broker
Arden Partners plc 020 7614 5900
Ciaran Walsh
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
info@turnerpope.com
Andy Thacker
Zoe Alexander
This announcement contains Inside Information as defined under
the Market Abuse Regulation (EU) No. 596/2014.
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary oesophageal Doppler
monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity
in the central circulation in real time. Minimally invasive, easy
to set-up and quick to focus, the technology generates a
low-frequency ultrasound signal which is highly sensitive to
changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic
space to have built a robust and credible evidence base
demonstrating both the clinical and economic benefits of its core
technology, TrueVue Doppler. This technology has been proven in a
wide range of clinical trials to reduce complications suffered by
patients after surgery and consequently save hospitals the costs of
treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocol for surgical patients.
Consequently, the Group's focus is on maximising value from the
opportunities presented, as enhanced haemodynamic management is
adopted into routine clinical practice around the world. The Group
aims to provide clinicians with a single platform - a 'haemodynamic
workstation' - which offers them a range of technologies from
simple to sophisticated to be deployed according to the patient's
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOABLBDGXGGBGCS
(END) Dow Jones Newswires
October 07, 2019 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024